Compare FCBC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCBC | DRUG |
|---|---|---|
| Founded | 1874 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.7M | 707.1M |
| IPO Year | 1996 | 2020 |
| Metric | FCBC | DRUG |
|---|---|---|
| Price | $42.37 | $82.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $129.25 |
| AVG Volume (30 Days) | 56.3K | ★ 195.9K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.28 | N/A |
| Revenue Next Year | $2.55 | N/A |
| P/E Ratio | $67.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.21 | $23.18 |
| 52 Week High | $44.36 | $123.75 |
| Indicator | FCBC | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 50.80 |
| Support Level | $42.14 | $79.55 |
| Resistance Level | $44.20 | $84.29 |
| Average True Range (ATR) | 1.09 | 4.91 |
| MACD | -0.07 | -0.47 |
| Stochastic Oscillator | 49.56 | 61.99 |
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.